Ticker: MREO

Snapshot - Mereo BioPharma Group plc (NASDAQ: MREO) What's happening inside: the company is advancing late‑stage rare‑disease programs (setrusumab and alvelestat), progressing Phase 3 activity with partner Ultragenyx, converting debt to equity to reduce interest burden, and recognizing a small li...

Mereo BioPharma Group PLC (NASDAQ: MREO) has recently released its financial results for the first quarter of 2025, revealing both challenges and opportunities for the biopharmaceutical company focused on developing innovative therapeutics for rare diseases. Key points and statistics: Net Loss: ...